Abstract
In this crossover study of ezetimibe monotherapy in 48 antiretroviral-treated patients with human immunodeficiency virus infection, the mean changes in low-density lipoprotein cholesterol were -5.3% (-11 mg/dL) and +5.5% (+4 mg/dL) with ezetimibe treatment and placebo, respectively (P = .04). Ezetimibe was safe and effective in reducing low-density lipoprotein cholesterol and is an option for patients who cannot tolerate treatment with a statin.
Publication types
-
Randomized Controlled Trial
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Anti-HIV Agents / adverse effects*
-
Anti-HIV Agents / pharmacology*
-
Antiretroviral Therapy, Highly Active / adverse effects*
-
Azetidines / pharmacology*
-
Cholesterol, LDL / blood*
-
Ezetimibe
-
Female
-
HIV Infections / complications*
-
HIV Infections / drug therapy*
-
Humans
-
Hypercholesterolemia / chemically induced*
-
Male
-
Middle Aged
-
Placebos / administration & dosage
Substances
-
Anti-HIV Agents
-
Azetidines
-
Cholesterol, LDL
-
Placebos
-
Ezetimibe